Beth Hecht - 31 Jan 2024 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Legal Officer and Corporate Secretary
Signature
/s/ Beth Hecht
Issuer symbol
XERS
Transactions as of
31 Jan 2024
Net transactions value
$0
Form type
4
Filing time
31 Jan 2024, 17:04:44 UTC
Previous filing
15 Jun 2023
Next filing
07 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +750,000 +93% $0.000000 1,554,968 31 Jan 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
F2 These shares include 7,210 shares that were purchased on June 30, 2023 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan.

Remarks:

Chief Legal Officer and Corporate Secretary